CompletedNCT06607666
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
Studying Acromegaly
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Principal Investigator
- Sabrina ChiloiroFondazione Policlinico Universitario A. Gemelli, IRCCS
- Intervention
- Lanreotide autogel(drug)
- Enrollment
- 102 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC ENDOCRINOLOGIA, Roma, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06607666 on ClinicalTrials.govOther trials for Acromegaly
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06930625A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsDebiopharm International SA
- RECRUITINGPHASE2NCT07037420ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07179926Effects of Pasireotide Lar Therapy on Bone MetabolismFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE1NCT07195175Study of MAR002 in Healthy MenMarea Therapeutics
- RECRUITINGNCT06597383The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In AcromegalyIRCCS San Raffaele
- RECRUITINGNANCT06949891KETOgenic Diet Therapy in Patients With ACROmegalyErasmus Medical Center
- RECRUITINGNCT06344650Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.IRCCS San Raffaele
- RECRUITINGNCT05131100Korean Regulatory Post Marketing Surveillance for SomavertPfizer